Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · IEX Real-Time Price · USD
58.00
+4.97 (9.37%)
At close: Jul 19, 2024, 4:00 PM
59.02
+1.02 (1.76%)
Pre-market: Jul 22, 2024, 8:21 AM EDT
CRBP Employees
Corbus Pharmaceuticals Holdings had 19 employees as of December 31, 2023. The number of employees decreased by 14 or -42.42% compared to the previous year.
Employees
19
Change (1Y)
-14
Growth (1Y)
-42.42%
Revenue / Employee
n/a
Profits / Employee
-$1,776,699
Market Cap
619.83M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
PetIQ | 1,933 |
Ginkgo Bioworks Holdings | 1,218 |
REGENXBIO | 344 |
ProKidney | 163 |
Entrada Therapeutics | 159 |
KalVista Pharmaceuticals | 150 |
Astria Therapeutics | 59 |
Celcuity | 55 |
CRBP News
- 7 weeks ago - SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024 - GlobeNewsWire
- 7 weeks ago - Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC - GlobeNewsWire